21:36 , May 16, 2019 |  BC Extra  |  Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's second round of Quick Takes on selected abstracts (see "May 15 ASCO...
23:45 , May 9, 2019 |  BC Extra  |  Company News

May 9 Company Quick Takes: Chimerix, Puma, Janssen

Chimerix abandons brincidofovir trials  Chimerix Inc. (NASDAQ:CMRX) will cut its workforce in half after deciding to discontinue all clinical trials of adenovirus candidate brincidofovir due to low patient recruitment, five years after access to the...
21:58 , Apr 26, 2019 |  BioCentury  |  Product Development

Rise of the independents, biotechs go to market

While product launch and commercialization has largely been the province of big biotech and big pharma, with smaller companies partnering to get their products over the finish line, BioCentury’s analysis of recent FDA approvals finds...
17:15 , Apr 5, 2019 |  BC Week In Review  |  Company News

Pierre Fabre gets European, African rights to Puma's Nerlynx

Pierre Fabre will pay $60 million up front for commercialization rights to Puma's Nerlynx neratinib in Europe, excluding Russia and Ukraine, and in certain North and West African countries. Puma Biotechnology Inc. (NASDAQ:PBYI) is also...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
17:28 , Nov 9, 2018 |  BC Week In Review  |  Company News

Earnings roundup: Puma falls on Nerlynx sales miss; cabozantinib sales lift Exelixis

Puma Biotechnology Inc. (NASDAQ:PBYI) shares tumbled, while Exelixis Inc. (NASDAQ:EXEL) gained after the companies reported 3Q18 financial results for their flagship therapies. Puma lost $18.53 (48%) to $20.07 on Nov. 2 after the company said...
21:06 , Nov 2, 2018 |  BC Extra  |  Company News

Earnings roundup: Puma falls on Nerlynx sales miss; cabozantinib sales lift Exelixis

Puma Biotechnology Inc. (NASDAQ:PBYI) shares tumbled, while Exelixis Inc. (NASDAQ:EXEL) gained after the companies reported 3Q18 financial results for their flagship therapies. Puma lost $18.53 (48%) to $20.07 Friday after the company said the discontinuation...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
19:57 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Canbridge submits NDA in China for breast cancer drug Nerlynx

Canbridge Life Sciences Ltd. (Beijing, China) said China's National Medical Products Administration (NMPA) accepted an NDA for Nerlynx neratinib as an extended adjuvant treatment for adult patients with early stage HER2-positive breast cancer following adjuvant...
18:44 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

EC approves Puma's Nerlynx as adjuvant for breast cancer

The European Commission approved Nerlynx neratinib from Puma Biotechnology Inc. (NASDAQ:PBYI) for extended adjuvant treatment of adults with early hormone receptor-positive, HER2-overexpressed/amplified breast cancer within one year of completion of prior adjuvant Herceptin trastuzumab-based therapy....